Massachusetts-Based Consano Bio Raises Over $15M in Funding

Consano Bio, a Boston, Massachusetts-based biotechnology company developing treatments for serious and painful orthopedic conditions, has raised more than $15 million in a financing round. The funding brings the company's total raised to more than $45 million.

The company will use the funds to advance its research and development efforts and complete the ongoing clinical trial of its lead candidate, C-1101.

What is Consano Bio?

Consano Bio is developing biologic therapeutics for painful and debilitating orthopedic conditions.

Read More:AI Startup Valon Raises $150M in Series D Funding

The company's lead program, C-1101, is being studied as a potential treatment for chronic painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica.

The company is also working to strengthen the scientific foundation and intellectual property portfolio around C-1101 and additional therapeutic programs.

How Much Funding Has Consano Bio Raised?

Consano Bio has raised more than $15 million in its latest financing round.

Including this financing, the company has raised more than $45 million since its inception three years ago.

The investors in the latest round were not disclosed.

Why the Funding Matters

Consano Bio will use the funding to complete its ongoing randomized, double-blind Phase 1 clinical trial of C-1101.

The company will also continue developing C-1101 and additional assets while strengthening its scientific and intellectual property foundation.

The Phase 1 study is enrolling patients with chronic painful LSR in Australia and the United States and is expected to complete enrollment in early 2027.

Market and Business Growth

Consano Bio is currently advancing C-1101 through Phase 1 clinical development.

The company is studying the treatment in patients with chronic painful LSR, or chronic sciatica. The trial is being conducted in Australia and the United States.

The FDA granted C-1101 Fast Track designation for the treatment of LSR in August 2026.

Clinical data from the Phase 1 study are expected in the first half of 2027 and will help inform the company's future clinical development plans.

What Happens Next?

Consano Bio plans to complete enrollment in its Phase 1 trial in early 2027 and expects to receive clinical data in the first half of 2027.

The company will also continue developing C-1101 and its additional therapeutic programs.

"C-1101 represents a new category of disease-modifying biologics, designed to activate cellular repair and alleviate the pain and dysfunction that result from orthopedic conditions. LSR is where we begin, and we believe the potential of this approach extends well beyond a single condition," said Andrew Hall, Chief Executive Officer of Consano Bio.

Read More:California-Based Clockwork.io Secures $31M in Funding